- NCIt
- C9226
Loading cancer entity…
Loading cancer entity…
Clinical trials
10 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05077384 | Open-label Study of Surufatinib in Japanese Patients | completed | Phase 1 / Phase 2 | 36 | HutchmedINDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT05968170 | TCRαβ/CD19 Depletion of Stem Cell Grafts for Transplant | withdrawn | N/A | 0 | Neena Kapoor, M.D.OTHER | 0 | Jul 14, 2025 | clinicaltrials |
| NCT02586389 |
| recruiting |
| — |
| 3,000 |
| Sequenom, Inc.INDUSTRY |
| 1 |
| Oct 16, 2024 |
| clinicaltrials |
| NCT04285242 | Metabolic and Immunological Phenotyping in Patients With Cancer(MIPPaC) | unknown | — | 80 | CCTU- Cancer ThemeOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT03625557 | Guardant360® Test-Related Clinical Outcomes in Patients Who Share Medical Records | completed | — | 30 | Guardant Health, Inc.INDUSTRY | 1 | Apr 17, 2020 | clinicaltrials |
| NCT02412722 | A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies | completed | Phase 1 | 61 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 28, 2020 | clinicaltrials |
| NCT01849744 | Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies | terminated | Phase 1 | 48 | Verastem, Inc.INDUSTRY | 1 | Jul 28, 2017 | clinicaltrials |
| NCT01943292 | Phase I Dose Escalation Study of VS-6063 in Japanese Subjects With Non-Hematologic Malignancies | completed | Phase 1 | 9 | Verastem, Inc.INDUSTRY | 1 | Mar 9, 2017 | clinicaltrials |
| NCT01991938 | Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma | terminated | Phase 1 | 75 | Verastem, Inc.INDUSTRY | 2 | Jan 27, 2017 | clinicaltrials |
| NCT01799421 | Risk Assessment of Febrile Neutropenia and Grade 3-4 Neutropenia in Patients With Non-hematological Cancer Treated With Conventional Chemotherapy(NEURISK) | completed | — | 420 | Asociación para el Fomento de la Investigación y el Desarrollo Integral de la OncologíaOTHER | 1 | Nov 21, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Sep 16, 2025source: clinicaltrials